Literature DB >> 18650510

Tier 4 drugs and the fraying of the social compact.

Thomas H Lee1, Ezekiel J Emanuel.   

Abstract

Mesh：

Substances：

Year:  2008        PMID： 18650510     DOI： 10.1056/NEJMp0804261

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  22 in total

1.  Growth hormone and health policy.

Authors:  Leona Cuttler; J B Silvers
Journal:  J Clin Endocrinol Metab       Date:  2010-04-28       Impact factor: 5.958

2.  Enhancing the rational use of new medicines across European health care systems.

Authors:  Silvio Garattini; Vittorio Bertele'; Brian Godman; Alan Haycox; Björn Wettermark; Lars L Gustafsson
Journal:  Eur J Clin Pharmacol       Date:  2008-12       Impact factor: 2.953

Review 3.  mAbs: a business perspective.

Authors:  Pablo A Scolnik
Journal:  MAbs       Date:  2009-03-21       Impact factor: 5.857

4.  Expensive cancer drugs: a comparison between the United States and the United Kingdom.

Authors:  Ruth R Faden; Kalipso Chalkidou; John Appleby; Hugh R Waters; Jonathon P Leider
Journal:  Milbank Q       Date:  2009-12       Impact factor: 4.911

Review 5.  Cost, coverage, and comparative effectiveness research: the critical issues for oncology.

Authors:  Steven D Pearson
Journal:  J Clin Oncol       Date:  2012-10-15       Impact factor: 44.544

6.  Out of pocket, out of sight? An unmeasured component of the burden of cancer.

Authors:  Matthew P Banegas; K Robin Yabroff
Journal:  J Natl Cancer Inst       Date:  2013-01-24       Impact factor: 13.506

7.  Making the case for talking to patients about the costs of end-of-life care.

Authors:  Greer Donley; Marion Danis
Journal:  J Law Med Ethics       Date:  2011       Impact factor: 1.718

8.  Do changes in drug coverage policy point to an increased role for cost-effectiveness analysis in the USA?

Authors:  James D Chambers
Journal:  Pharmacoeconomics       Date:  2014-08       Impact factor: 4.981

9.  Forecasting drug utilization and expenditure in a metropolitan health region.

Authors:  Björn Wettermark; Marie E Persson; Nils Wilking; Mats Kalin; Seher Korkmaz; Paul Hjemdahl; Brian Godman; Max Petzold; Lars L Gustafsson
Journal:  BMC Health Serv Res       Date:  2010-05-17       Impact factor: 2.655

Review 10.  Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers.

Authors:  Jakub Adamski; Brian Godman; Gabriella Ofierska-Sujkowska; Bogusława Osińska; Harald Herholz; Kamila Wendykowska; Ott Laius; Saira Jan; Catherine Sermet; Corrine Zara; Marija Kalaba; Roland Gustafsson; Kristina Garuolienè; Alan Haycox; Silvio Garattini; Lars L Gustafsson
Journal:  BMC Health Serv Res       Date:  2010-06-07       Impact factor: 2.655
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.